Investors

/Investors
Investors 2018-09-06T09:30:38+00:00

Oramed Pharmaceuticals Inc.
(ORMP) – NasdaqCM

4.89
0.04 (0.82%)
Refresh Quote
Exchange :NASDAQ (US Dollar)
Ric Code :ORMP
Volume :18,107
Date :09-21-2018

* Minimum 20 minute delay See terms

Oramed Pharmaceuticals (NASDAQ: ORMP) has developed innovative technology to transform injectable treatments into oral therapies.

Oramed’s flagship product, an oral insulin capsule, can better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles… [READ MORE >]

Oramed Receives FDA Clearance for IND Application for Its Oral GLP-1 Analog Capsule

September 17th, 2018|Comments Off on Oramed Receives FDA Clearance for IND Application for Its Oral GLP-1 Analog Capsule

NEW YORK, Sept. 17, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the U.S. Food and [...]

Oramed to Present at the H.C. Wainwright Global Investment Conference

August 28th, 2018|Comments Off on Oramed to Present at the H.C. Wainwright Global Investment Conference

NEW YORK, Aug. 28, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com),  a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate [...]

Oramed Granted Japanese Patent for GLP-1 Analog Capsule

July 24th, 2018|Comments Off on Oramed Granted Japanese Patent for GLP-1 Analog Capsule

NEW YORK, July 24, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Japanese Intellectual Property [...]

Oramed Announces Closing of $18.1 Million Registered Direct Offering

July 6th, 2018|Comments Off on Oramed Announces Closing of $18.1 Million Registered Direct Offering

NEW YORK, July 6, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the closing of its previously-announced registered direct [...]